Alto Neuroscience, Inc. Interest Expense Nonoperating
Alto Neuroscience, Inc. (ANRO) reported Interest Expense Nonoperating of $491.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-08-12
- Alto Neuroscience, Inc. interest expense nonoperating for the quarter ending 2026-06-30 was $491.00K, a 23.99% decline year-over-year.
- Alto Neuroscience, Inc. interest expense nonoperating for the quarter ending 2026-03-31 was $545.00K, a 8.86% decline year-over-year.
- Alto Neuroscience, Inc. interest expense nonoperating for the quarter ending 2025-12-31 was $575.00K, a 72.67% increase year-over-year.
- Alto Neuroscience, Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $650.00K, a 86.25% increase year-over-year.
- Alto Neuroscience, Inc. interest expense nonoperating for fiscal 2025 was $2.47M, a 79.56% increase from fiscal 2024.
- Alto Neuroscience, Inc. interest expense nonoperating for fiscal 2024 was $1.38M, a 0.36% increase from fiscal 2023.
- Alto Neuroscience, Inc. interest expense nonoperating for fiscal 2023 was $1.37M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $491.00K 10-Q · filed 2026-08-12 | $1.04M 10-Q · filed 2026-08-12 | $1.61M derived: sum of 3 quarters · filed 2026-08-12 | $2.26M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $545.00K 10-Q · filed 2026-05-13 | $1.12M derived: sum of 2 quarters · filed 2026-05-13 | $1.77M derived: sum of 3 quarters · filed 2026-05-13 | $2.42M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $575.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $1.23M derived: sum of 2 quarters · filed 2026-03-16 | $1.87M derived: sum of 3 quarters · filed 2026-08-12 | $2.47M 10-K · filed 2026-03-16 |
| 2025-09-30 | $650.00K 10-Q · filed 2025-11-12 | $1.30M derived: sum of 2 quarters · filed 2026-08-12 | $1.89M 10-Q · filed 2025-11-12 | $2.23M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $646.00K 10-Q · filed 2026-08-12 | $1.24M 10-Q · filed 2026-08-12 | $1.58M derived: sum of 3 quarters · filed 2026-08-12 | $1.93M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $598.00K 10-Q · filed 2026-05-13 | $931.00K derived: sum of 2 quarters · filed 2026-05-13 | $1.28M derived: sum of 3 quarters · filed 2026-05-13 | $1.63M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $333.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $682.00K derived: sum of 2 quarters · filed 2026-03-16 | $1.03M derived: sum of 3 quarters · filed 2026-03-16 | $1.38M 10-K · filed 2026-03-16 |
| 2024-09-30 | $349.00K 10-Q · filed 2025-11-12 | $696.00K derived: sum of 2 quarters · filed 2025-11-12 | $1.04M 10-Q · filed 2025-11-12 | $1.40M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $347.00K 10-Q · filed 2025-08-13 | $693.00K 10-Q · filed 2025-08-13 | $1.05M derived: sum of 3 quarters · filed 2025-08-13 | $1.41M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $346.00K 10-Q · filed 2025-05-14 | $702.00K derived: sum of 2 quarters · filed 2025-05-14 | $1.06M derived: sum of 3 quarters · filed 2025-05-14 | $1.39M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $356.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $719.00K derived: sum of 2 quarters · filed 2025-03-20 | $1.05M derived: sum of 3 quarters · filed 2025-03-20 | $1.37M 10-K · filed 2025-03-20 |
| 2023-09-30 | $363.00K 10-Q · filed 2024-11-12 | $690.00K derived: sum of 2 quarters · filed 2024-11-12 | $1.01M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $327.00K 10-Q · filed 2024-08-13 | $651.00K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $324.00K 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |